IMCR实时信号 | 通过Getagraph.com最大化利润

购买 107351 min ago

@ $71.91

发出时间: 15 Feb 2024 @ 04:47

回报率: -18.70%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: -2.49 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases...

Stats
今日成交量	403 551
平均成交量	512 688
市值	2.91B
EPS	$0 ( 2024-02-28 )
下一个收益日期	( $-0.320 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-41.17
ATR14	$0.0510 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	St Leger Tina Amber	Sell	4 375	Employee Share Option (Right to Buy)
2024-04-01	St Leger Tina Amber	Buy	4 375	Ordinary Shares
2024-04-01	St Leger Tina Amber	Sell	4 375	Ordinary Shares
2024-02-28	Berman David M	Sell	36 509	Employee Share Option (Right to Buy)
2024-02-28	Berman David M	Buy	36 509	Ordinary Shares

INSIDER POWER
-75.94
Last 63 transactions
Buy: 607 651 \| Sell: 4 752 433

音量相关性

長: 0.49 (neutral)

短: 0.68 (moderate)

Signal:(74.516) Neutral

Immunocore Holdings plc 相关性

10 最正相关
AMRB	0.859
LWAC	0.837
MMAC	0.835

10 最负相关
SVAC	-0.83
TLGT	-0.821

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Immunocore Holdings plc 相关性 - 货币/商品

0.62
( weak )

0.55
( weak )

0.00
( neutral )

0.62
( weak )

-0.46
( neutral )

-0.56
( weak negative )

Immunocore Holdings plc 财务报表

Annual	2023
营收:	$249.43M
毛利润:	$248.39M (99.58 %)
EPS:	$-0.00110

FY	2023
营收:	$249.43M
毛利润:	$248.39M (99.58 %)
EPS:	$-0.00110

FY	2022
营收:	$143.74M
毛利润:	$143.28M (99.68 %)
EPS:	$-0.900

FY	2021
营收:	$26.52M
毛利润:	$0.00 (0.00 %)
EPS:	$-3.10

Financial Reports:

No articles found.

Immunocore Holdings plc

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.